3 models fit Universal Health Services Inc. Common Stock and they disagree: 0 of 3 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)Gold84
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionUniversal Health Services Inc. Common Stock (UHS)
Fair value (3 models)
$309
ACCE price target
$205
Rating
Undervalued
Horizon
12 months
Fair value published on 19 Oct 2026, 19:04 CEST; previously $376 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 27 Sept 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 19:04 CEST.
Price used: $187 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
39.6% below
+65.6% to fair value
ACCE score
71
out of 100
Analysts
35% buy
20 covering
P/E
7.7x
forward 7.3x
1-year return
-10.4%
Dividend yield
0.44%
Universal Health Services Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Universal Health Services runs acute care hospitals and behavioral health facilities across the US and the UK, and it is one of the few large operators with meaningful scale in psychiatric inpatient care, a segment where bed capacity is hard to build quickly. That scarcity gives it pricing and referral leverage that general acute hospitals often lack. Revenue is growing 8.3% with a 44.6% gross margin and an 11.1% operating margin, and return on equity of 20.9% suggests the capital base is being used efficiently. At a trailing P/E of 7.3 and a forward P/E of 7.5, the market is pricing in little growth, which makes the company worth a closer look to test whether behavioral demand and bed additions can keep margins from compressing. The key diligence questions are payer mix, Medicaid and exchange exposure, and how much of recent growth came from volume versus rate.